Abstract
Aim
Telomeres are regions of highly repetitive, non-coding DNA located at the termini of chromosomes whose principal function is to maintain the structural stability of these ends. In 90% of human tumours, telomere length is maintained by the expression and activation of telomerase reverse transcriptase. Various studies have demonstrated an increase in telomerase activity in tumour tissue, which suggests its possible prognostic value. The main objective of our study was to study the prognostic value of the expression level of telomerase catalytic component (hTERT) in patients with colorectal cancer (CRC).
Methods
We analysed the prognostic value of the ratio of telomerase expression in tumour tissue to telomerase expression in the adjacent healthy mucosa and the prognostic value of the expression level of hTERT in the serum of patients diagnosed with CRC. As secondary objectives of the study, we (1) analysed the correlation between telomerase expression in the serum and that in the tumour tissue and (2) analysed the relationship between telomerase expression and different clinical parameters.
Results
Peripheral blood and tissue samples taken from 48 patients with CRC were analysed. No significant differences were observed in disease-free survival (DFS) or overall survival time (OST) between the groups of patients categorised based on the ratio of telomerase expression between tumour tissue and healthy tissue. The correlation index (Pearson’s coefficient) between telomerase levels in the serum and those in tissue was 0.32. Our study of the relationship between telomerase levels in the serum and different clinical variables, such as tumour size, ganglion affectation, preoperative carcinoembryonic antigen levels and stage, revealed a higher telomerase expression level in patients with stage IV CRC. There was no significant association between telomerase expression in tumour tissue and the clinical parameters analysed.
Conclusions
The results obtained in our study do not allow us to propose that the level of telomerase expression be used as a prognostic factor in colorectal cancer. Thus, we cannot consider telomerase expression in the serum as a surrogate marker of its expression in tumour tissue.
Similar content being viewed by others
References
Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622
Hahn WC, Weinberg RA (2002) Rules for making humor tumor cells. N Engl J Med 347:1593–1603
Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015
Hiyama E, Gollahan L, Kataoka T et al (1995) Telomerase activity in gastric cancer. Cancer Res 55:3258–3262
Tahara H, Kuniyasu H, Yokozaki H et al (1995) Telomerase activity in preneoplasic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1:1245–1251
Hiyama E, Kodama T, Sinbara K et al (1997) Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57: 326–331
Engelhardt M, Drullinsky P, Guillem J et al (1997) Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 3:1931–1941
Shay JW, Werbin H, Wright WE (1997) Telomerase assay in the diagnosis and prognosis of cancer. CIBA Found Symp 211:148–155
Saleh S, Lam AK, Ho YH (2008) Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology 40:25–30
Kanamaru T, Tanaka K, Kotani J et al (2002) Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer. Int J Mol Med 10:205–210
Gonzalo V, Petit A, Castellví-Bel S et al (2010) Telomerase mRNA expression and immunohis-tochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. Gastroenterol Hepatol 33:288–296
Hiyama K, Hirai Y, Kyoizumi et al (1995) Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711–3715
Taylor RS, Ramirez RD, Ogoshi M et al (1996) Detection of telomerase activity in malignant and nonmalignant skin condition. J Invest Dermatol 106:756–765
Hiyama E, Hiyama K, Tatsumoto N et al (1996) Telomerase activity in human intestine. Int J Oncol 9:453–458
Tatsumoto N, Hiyama E, Murakami Y et al (2000) High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 6:2696–2701
Gertler R, Rosenberg R, Stricker D et al (2002) Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 95:2103–2111
Gertler R, Rosenberg R, Stricker D et al (2004) Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis on colorectal carcinoma. J Clin Oncol 22:1807–1814
Boldrini L, Faviana P, Gisfredi S et al (2004) Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncol Rep 11:395–400
Garcia-Aranda C, de Juan C, Diaz-Lopez A et al (2006) Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 106: 541–551
Hess JL, Highsmith E (2002) Telomerase detection in body fluids. Clin Chem 48:18–24
Cheng X, Bonnefoi H, Pelte M-F et al (2000) Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 6:3823–3826
Ohnishi T, Watanabe T, Nozawa H et al (2008) Telomerase activity of blood samples and recurrence of colorectal cancer. Hepatogastroenterology 55:1513–1518
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safont, M.J., Gil, M., Sirera, R. et al. The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. Clin Transl Oncol 13, 396–400 (2011). https://doi.org/10.1007/s12094-011-0673-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0673-2